Mecort Tablet contains Methylprednisolone, a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties. It is primarily indicated for the management of various inflammatory and autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, allergic reactions, asthma, and certain dermatological disorders. Methylprednisolone exerts its therapeutic effects by modulating the immune response and inhibiting the release of inflammatory mediators, thereby reducing tissue inflammation and immune system activity. Mecort is also utilized in the treatment of adrenal insufficiency and as part of adjunctive therapy in certain malignancies. The dosage and duration of therapy with Mecort Tablet should be individualized based on the severity of the condition and patient response, with careful monitoring to minimize potential adverse effects such as immunosuppression, hyperglycemia, osteoporosis, and gastrointestinal disturbances. Abrupt discontinuation should be avoided to prevent adrenal insufficiency; tapering the dose under medical supervision is recommended. Contraindications include systemic fungal infections and known hypersensitivity to corticosteroids. Mecort Tablet should be used cautiously in patients with diabetes, hypertension, peptic ulcer disease, and psychiatric disorders. Regular follow-up and laboratory assessments are essential to ensure therapeutic efficacy and safety during treatment.